Time for TED thread on MAM.
I hold so this is probably a blatant ramp, but take a look.
The share is now off its low of 11.5p.
Although many got burnt in thr over hype a few years ago, I think the company
Is now well positioned for advancement.
Management have said that more Nucleopure machine sales are in the pipeline.

Have a listen to TEDs CE here, http://www.wallstreetreporter.com/profiles/TepnelLifeSciences.html

Guardian
Finally, it's worth keeping an eye on Tepnel Life Sciences. Market professionals reckon the AIM-listed DNA technology group has been overlooked in the past month and could now enjoy a good run. They note directors recently bought stock and point out that Tepnel's acquisition of Orchid Diagnostics should significantly boost the company's revenue stream and help it reach a much broader customer base. Tepnel closed 0.5p higher at 13p last night.

Sunday Telegraph
Tepnel is close to completing a second acquisition, having just bought the DNA-testing division of Orchid BioSciences, which allows it to enter the US market and increase the customer base for its DNA technology. Buy at 14.25p, the paper says.
regards
dave

Toya, TED posted their last interims 5/9/07 I didn't realise they were due out so soon. Thanks, Good Luck.
2517

Pretty sure I read that on their website - we'll soon know!

Substantial increase in revenues and profits


Manchester, UK, Stamford, USA, 31 July 2008: Tepnel Life Sciences plc (AIM: TED), the international Molecular Diagnostics and Research Products and Services Group, announces interim results for the 6 month period ended 30 June 2008.


'Tepnel continues to deliver very strong revenue and operating profit growth across its entire business. Our new purpose built, state-of-the-art pharmaceutical services facility, along with our recently launched Biopharmaceutical and Genotyping services, have been a great success with strong customer demand.

Additionally, Tepnel's immunological products are showing good growth and have now begun to penetrate worldwide markets. Tepnel's Molecular Diagnostics division also continues to exhibit strong growth led by our LifeMatch range of products and our Elucigene CF and QST*R genetic tests' stated Ben Matzilevich, Tepnel's Chief Executive Officer. 'We believe Tepnel is very well positioned for future growth bolstered by a growing menu of novel molecular diagnostic products and demand for our advanced pharmaceutical outsourcing services. Our strong H1 performance and positive outlook are testament to the loyalty, commitment and dedication of Tepnel's staff and shareholders alike.'


2008 Highlights


*

Revenue increased to 11.8m from 8.8m, an increase of 34% compared to the prior period and 29% on a constant currency basis

*

Gross profit increased 34% to 6.9m compared to 5.1m in 2007

*

An increase of 149% in operating profit to 1.5m from 0.6m in 2007

*

EBITDA increased 118% to 1.9m from 0.9m in 2007

*

Operating cash inflow increased to 1.5m from a cash outflow of 0.2m in 2007

*

Tepnel continues to deliver significant and sustained growth in both revenue and operating profit across both divisions in line with its strategic and operational plans:

Research Products and Services revenue increased by 28% driven by the strong demand for its pharmaceutical outsourcing services from its new state-of-the-art facility in Livingston and newly introduced Biopharmaceutical and Genotyping service lines


Molecular Diagnostics revenue increased by 39% driven by the Transplant Diagnostics business line. The LifeMatch range of products continued to show strong growth compared to the prior period

Back from a couple of weeks in Austria, TED doing very nicely.
2517

isit time to sell

A very steep climb indeed! I wouldn't want to buy just now.

BAYLIS well called, in the short term at least. Longer term I believe the management are going to take TED much further than current sp but, like all shares after a burst upwards some profit taking is desirable.
Toya, rather belatedly, you were correct about the timing of results. Good luck all.
2517

George: I agree with you, Tepnel looks like a promising little pharmaco; not sure that it's pulled back enough to buy for longer term just yet though. 9.5-10p would look reasonable. Chairman, Finance Director, and a third director topped up recently.

Approach for the co.
2517

If TED is taken over then somewhere north of 19p should be achieved, imo.
2517

Good volume (for TED) yesterday and again today.
2517

Still going strong on a possible takeover and may well continue upwards, no certainty of the takeover so have sold today @ 19p for a nice profit. Good luck to all remaining shareholders.
2517

miss you george

XSTEFFX---very kind of you thanks, I won't be far away. I held these in certificate form dated February 2004, so it's been a longish hold especially with no dividends, I think the management have done an excellent job over the last 2 years or so, and if the bid does not materialise I will be back in on the lower sp. Good luck.
2517

RECOMMENDED CASH OFFER FOR TEPNEL LIFE SCIENCES PLC


Summary


*

The Gen-Probe Directors and Tepnel Directors are pleased to announce that they have reached agreement on the terms of a recommended cash offer to be made by Gen-Probe for the entire issued and to be issued share capital of Tepnel. It is intended that the Offer will be effected by means of a scheme of arrangement under the Companies Act 2006.


*

Under the terms of the Offer, Tepnel Shareholders will receive 27.1 pence in cash for each Tepnel Share.


*

The Offer values each Tepnel Share at 27.1 pence and the fully diluted share capital of Tepnel at approximately 92.8 million ($132.2 million).


*

The Offer represents a premium of approximately:


*

125.8 per cent. to the closing price of Tepnel Shares of 12.0 pence per Tepnel Share on 21 January 2009, being the last business day immediately prior to the announcement by Tepnel that it had received an approach; and


*

162.4 per cent. to 10.3 pence, being the average closing price per Tepnel Share over the 12 months prior to 21 January 2009.


*

Gen-Probe (NASDAQ: GPRO), based in San Diego, California, is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid probe-based products used primarily for the clinical diagnosis of human diseases and for screening donated human blood.


*

Tepnel (AIM: TED) is a UK-based international life sciences products and services group with two divisions, Molecular Diagnostics and Research Products & Services. The Company has laboratories, manufacturing and operations in the USA, UK, France and Belgium with over 200 employees. Tepnel provides test kits, reagents and services to two highly synergistic markets, Molecular Diagnostics and Biomedical Research.


*

The acquisition of Tepnel will allow Gen-Probe to enter the human leukocyte antigen, or HLA, and genetic testing segments. HLA testing, frequently conducted prior to transplantation and in the ongoing monitoring of transplant recipients, represents a significant product expansion area for Gen-Probe. In addition, Tepnel brings established pharmaceutical relationships and an opportunity for Gen-Probe to expand into the area of companion diagnostics. Gen-Probe further anticipates that its established capabilities in the research and development of novel diagnostics will help Tepnel accelerate its molecular diagnostics activities, including in the area of genetic testing for inherited disorders. Tepnel also contributes to Gen-Probe's goal of expansion outside the United States. On a non-GAAP basis, Gen-Probe expects the acquisition to be neutral to the Company's 2009 EPS, and accretive to its 2010 EPS.


*

The Tepnel Directors, who have been so advised by Seymour Pierce, consider the terms of the Offer to be fair and reasonable. In providing their advice to the Tepnel Directors, Seymour Pierce have taken into account the commercial assessments of the Tepnel Directors. In addition, the Tepnel Directors consider the terms of the Offer to be in the best interests of Tepnel Shareholders as a whole.


*

Accordingly, the Tepnel Directors intend unanimously to recommend that Tepnel Shareholders vote in favour of the Scheme and the resolutions at the Court Meeting and the GM as the Tepnel Directors have irrevocably undertaken to do in respect of their own beneficial holdings, representing as at the date of this announcement, in aggregate, approximately 4 per cent. of the existing issued share capital of Tepnel.


*

Gen-Probe has received irrevocable undertakings from certain institutional shareholders to vote in favour of the Scheme and the resolutions at the Court Meeting and the GM in respect of their entire holdings representing, in aggregate, approximately 36 per cent. of the existing issued share capital of Tepnel. Gen-Probe has therefore received total irrevocable undertakings in respect of Tepnel Shares representing approximately 40 per cent. of the existing issued share capital of Tepnel.


*

Gen-Probe has also received irrevocable undertakings from certain Tepnel Directors and certain institutional shareholders to exercise Tepnel Share Warrants conditional upon the sanction of the Scheme by the Court representing approximately, in aggregate, 16 per cent. of the diluted share capital of Tepnel.


*

The Offer will be put to Tepnel Shareholders at the Court Meeting and at the GM. In order to become effective, the Scheme must be approved by a majority in number of the holders of Tepnel Shares present and voting, either in person or by proxy, representing at least 75 per cent. in value of the Tepnel Shares held by such Tepnel Shareholders at the Court Meeting. In addition, a special resolution implementing the Scheme and approving the related reduction of capital must be passed by Tepnel Shareholders representing 75 per cent. of the votes cast at the GM. The special resolution proposed at the GM will also approve related amendments to the articles of association of Tepnel and to certain of the Tepnel Share Schemes.


*

It is expected that the Scheme Document containing further details of the Offer will be posted on or around 21 February 2009. The Scheme will be subject, inter alia, to the satisfaction or waiver of the conditions set out in Appendix I to this announcement and in the Scheme Document.


*

It is expected that the Court Meeting and the General Meeting will be held on or around 16 March 2009 and that the Scheme will become effective on or around 8 April 2009.


Henry Nordhoff, Chairman and CEO of Gen-Probe, said:


'We believe our acquisition of Tepnel will provide us immediate access to attractive growth opportunities in transplant diagnostics, genetic testing and pharmaceutical services, and accelerate our ongoing strategic efforts to strengthen our marketing and sales, distribution and manufacturing capabilities in Europe. We look forward to working with the employees and customers of Tepnel to broaden the use of their innovative technologies and expand on their many successes to date.'


Ben Matzilevich, CEO of Tepnel, said:


'We believe Gen-Probe's offer represents significant value for Tepnel Shareholders and recognizes both our past achievements and our future potential in molecular diagnostics and pharmaceutical services. In addition, we are excited about the opportunity to accelerate our strategic plans as part of one of the most established and highly respected molecular diagnostics companies in the world.'


Merrill Lynch is acting as sole financial adviser and corporate broker to Gen-Probe. Seymour Pierce is acting as sole financial adviser and corporate broker to Tepnel.


This summary should be read in conjunction with, and is subject to, the full text of the following announcement and the Appendices. The Offer will be subject to the conditions set out in Appendix I to this announcement. Appendix II to this announcement contains the bases and sources of certain information contained in this announcement. Appendix III to this announcement contains details of the irrevocable undertakings. Appendix IV to this announcement contains a description of the principal terms of the Implementation Agreement. Appendix V contains the definitions of certain terms used in this summary.

I'm always happy to leave something for the next person, but I think I left too much ha! ha! Well done to all holders that's some premium as at 21st Jan.
2517

Espirito Santo Execution Noble Buy 1,627.00 1,470.00 1,150.00 1,650.00 Upgrades